<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619602</url>
  </required_header>
  <id_info>
    <org_study_id>BPD</org_study_id>
    <nct_id>NCT04619602</nct_id>
  </id_info>
  <brief_title>Inhaled Treatment for Bronchopulmonary Dysplasia</brief_title>
  <official_title>Pilot Study of an Inhaled Treatment for Bronchopulmonary Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to provide expanded access of S-nitrosylation therapy&#xD;
      for the treatment of bronchopulmonary dysplasia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label study with 20 participants, open-label, with block dose escalation of 3&#xD;
      subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM). A minimum of seven days of&#xD;
      surveillance will separate dosing blocks. An additional 11 subjects will be enrolled at the&#xD;
      maximum 1 mM block (5x10-7 moles/kg). The primary outcomes are safety during 30 minutes of&#xD;
      inhalation, and for 4 hours after inhalation, as measured by occurrence of adverse events&#xD;
      related to the treatment + time period [during administration and tracked for next 7 days].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>7 days</time_frame>
    <description>Occurrence of &gt;grade 3 adverse events related to the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>S-nitrosoglutathione change</measure>
    <time_frame>30 minutes</time_frame>
    <description>Percent change in S-nitrosoglutathione pre/post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen saturation index</measure>
    <time_frame>4 hours</time_frame>
    <description>Percent change in oxygen saturation index (O.S.I.) pre/post treatment. oxygen saturation index [O.S.I. = (FiO2) x (mean airway pressure) x 100 / (SpO2)]. High OSI scores indicate worse respiratory failure (high OSI = bad, low OSI = good).Scale range: zero - infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GSNO catabolism pre/post treatment</measure>
    <time_frame>30 minutes</time_frame>
    <description>Percent change in GSNO catabolism pre/post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intermittent hypoxemia as measured by oxygen saturation post treatment</measure>
    <time_frame>4 hours</time_frame>
    <description>Incidence, duration, and nadirs of intermittent hypoxemia (SpO2 &lt;80%) as measured by oxygen saturation parameters post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator parameters post treatment</measure>
    <time_frame>4 hours</time_frame>
    <description>Change in ventilator parameters post treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>GSNO therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSNO</intervention_name>
    <description>Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.</description>
    <arm_group_label>GSNO therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Inborn or outborn infants of either sex or any race or ethnicity&#xD;
&#xD;
          2. &lt;32 weeks gestation at birth (best obstetrical dating)&#xD;
&#xD;
          3. Aged 29 to 365 days&#xD;
&#xD;
          4. Refractory hypoxic respiratory failure (average daily FiO2 &gt;35% for 5 days)&#xD;
&#xD;
          5. Requires mechanical ventilation via endotracheal airway&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life-threatening congenital or acquired anomalies (lethal chromosomal,&#xD;
             thoracic/cardiac, brain)&#xD;
&#xD;
          2. Unstable condition defined as severe hypoxemia (FiO2 &gt;85% for &gt;24hrs), sepsis, or&#xD;
             hypotension&#xD;
&#xD;
          3. Baseline methemoglobin &gt; 3%, congenital methemoglobinemia, or a familial&#xD;
             hemoglobinopathy&#xD;
&#xD;
          4. On steroid to facilitate endotracheal extubation&#xD;
&#xD;
          5. Individuals on inhaled nitric oxide, a phosphodiesterase 5 (PDE-5) inhibitor, taking&#xD;
             allopurinol, β-adrenergic blockers, tricyclic antidepressants, meperidine (or related&#xD;
             CNS agents), or nitrates&#xD;
&#xD;
          6. Thrombocytopenia defined as &lt;50,000 platelets/µL on weekly NICU labs, clinical&#xD;
             evidence of bleeding, on an anti-coagulant, or individuals with an inherited or&#xD;
             acquired coagulation disorder&#xD;
&#xD;
          7. Anemia defined as a hemoglobin of &lt; 9 mg/dL on weekly NICU labs&#xD;
&#xD;
          8. Concerns for pre-existing liver damage defined as an AST/ALT &gt; 50 IU/L or direct&#xD;
             bilirubin &gt;1 mg/dL on weekly NICU labs&#xD;
&#xD;
          9. Concerns for acute kidney injury defined as a serum creatinine &gt; 0.7 mg/dL on weekly&#xD;
             NICU labs or 24-hr urine output &lt;1.0 ml/kg/hr during preceding 4 days&#xD;
&#xD;
         10. Patients that are ventilated with a device not certified for blending of aerosolized&#xD;
             solutions into the ventilator circuit&#xD;
&#xD;
         11. Physician of record opposed to enrolling the patient due to perceived safety concerns;&#xD;
             or any condition that does not allow the protocol to be followed safely&#xD;
&#xD;
         12. Subjects that have experienced cardiac arrest with CPR for longer than 30 minutes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>365 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Raffay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Raffay, MD</last_name>
    <phone>(216)844-3387</phone>
    <email>Thomas.Raffay@UHhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Raffay, MD</last_name>
      <phone>216-844-3387</phone>
      <email>Thomas.Raffay@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Raffay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Thomas Michael Raffay, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>bronchopulmonary dysplasia</keyword>
  <keyword>respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

